Skip to content
Head to head

Vertex Pharmaceuticals vs Regeneron Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: VRTX · REGN

Updated 9 minutes ago

1-year performance, rebased to 100

VRTX +18.7%REGN +31.4%
Regeneron Pharmaceuticals edges it on the scoreable measures. Regeneron Pharmaceuticals has the highest Quant Rating (71); Regeneron Pharmaceuticals has done best over the past year (+25%); Regeneron Pharmaceuticals trades cheapest on trailing earnings.
VRTXREGN
Snapshot
SectorBiotechnology--
Last price515.02920.69
Change today-1.08%-0.19%
1-year return+22.0%+25.4%
Market cap$130.58B$95.24B
52-week range412.27 – 568.67590.23 – 990.72
Valuation
P/E (TTM)33.1420.35
P/E percentile, own 5-yr range99th74th
P/B6.252.84
Dividend yield0.00%0.40%
Profitability & growth
EPS (TTM)15.3241.48
Net profit (TTM)$3.88B$4.29B
Revenue (TTM)$12.95B$16.90B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+11.8%+36.3%
Gross margin85.5%85.8%
Operating margin33.1%30.4%
Net margin30.7%28.5%
Free cash flow (TTM)$3.20B$3.63B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership96.8%90.9%
Insider activity (12mo)28 buy / 22 sell18 buy / 32 sell
Short interest (% of float)1.9%2.2%
Analyst consensus95% buy / 5% hold (21)70% buy / 30% hold (23)
Analyst price target$624 (+21%)$966 (+5%)
StockVane view
StockVane Quant RatingC (62)C (71)
Company
Employees6,40015,410
Founded19891988

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.